Jean-Michel Bolla | Immunology and Microbiology | Best Researcher Award

Dr. Jean-Michel Bolla | Immunology and Microbiology | Best Researcher Award

Dr. Jean Michel Bolla is a distinguished researcher specializing in microbiology, biochemistry, and antibiotic resistance. With over 30 years of experience, he has made significant contributions to understanding bacterial resistance mechanisms, particularly efflux-mediated resistance in Gram-negative bacteria. As the Director of Research at Inserm U-1261, he has led pioneering studies in bacterial physiology and virulence, as well as the development of screening platforms for antibiotic-resistant bacteria. His leadership in the Bac-Screen platform, which enables high-throughput screening of antimicrobial compounds, highlights his commitment to innovative research. Dr. Bolla has supervised multiple PhD students and postdoctoral researchers, securing major research funding from national and international agencies. His work has been recognized through invited talks at international conferences and a patent related to diagnostic tools for antibiotic resistance. Additionally, he has contributed significantly to academia through teaching roles at Aix-Marseille Université and Université de Corse. His research continues to shape the field of antimicrobial resistance, addressing one of the most pressing global health challenges. Through his expertise, leadership, and dedication to scientific advancement, Dr. Bolla has established himself as a leading figure in microbiology and antibiotic resistance research.

Professional Profile

Education

Dr. Jean Michel Bolla holds a PhD in Biochemistry and Molecular Biology from UPR9027 CNRS, Marseille, awarded in 1990. His doctoral research focused on protein export and assembly in Escherichia coli, conducted under the supervision of Dr. JM Pagès. Following his PhD, he pursued a postdoctoral fellowship at Inserm-APHP, Paris, where he worked on iron starvation responses in Listeria monocytogenes under Dr. P. Berche. His advanced training includes specialization in Campylobacter porins at the Laboratory Centre for Disease Control in Ottawa and Winnipeg, Canada in 1997 and 1998. In 2001, he obtained his Habilitation à Diriger des Recherches (HDR) from the Faculty of Medicine, Timone, Marseille, enabling him to supervise doctoral research. His extensive academic training has provided him with a strong foundation in molecular microbiology, biochemistry, and antibiotic resistance. Through continuous education and research, Dr. Bolla has developed a deep understanding of bacterial physiology, antimicrobial resistance mechanisms, and drug discovery. His educational background has been instrumental in shaping his career as a leading researcher in microbiology and antibiotic resistance, allowing him to contribute groundbreaking insights to the field.

Professional Experience

Dr. Jean Michel Bolla has had an illustrious career in research, spanning over three decades. He began as a postdoctoral researcher at Inserm-APHP, Paris, before joining Inserm as a Chargé de Recherche in 1992. Over the years, he advanced within Inserm, holding key research positions, and became Director of Research at U-1261 in 2018. He has led major research initiatives, including the establishment of the Bac-Screen platform, a high-throughput screening system for antibiotic resistance studies. From 2007 to 2011, he also served as an Associate Professor at the Université de Corse, where he contributed significantly to teaching and student mentorship. Throughout his career, Dr. Bolla has supervised seven PhD students and three postdoctoral researchers, demonstrating his commitment to training future scientists. He has been an invited speaker at multiple international conferences, sharing his expertise in antibiotic resistance. His ability to secure major research funding, including grants from CNRS, ANR, and FEAMPA, underscores his impact in the field. His leadership roles at Inserm and collaborations with various research institutions have solidified his reputation as an expert in microbiology and antibiotic resistance.

Research Interest

Dr. Jean Michel Bolla’s research primarily focuses on antibiotic resistance mechanisms, with a particular emphasis on efflux-mediated resistance in Gram-negative bacteria. His work explores the physiology and virulence of bacterial pathogens, including Campylobacter jejuni and Listeria monocytogenes. He is deeply involved in drug discovery and screening technologies, having developed the Bac-Screen platform to identify novel antimicrobial compounds and assess their mechanisms of action. His research also extends to bacterial membrane permeability, studying how bacterial outer membrane porins influence antibiotic uptake and resistance. More recently, he has been engaged in synthetic antibacterial polymer development for therapeutic applications. His work contributes to understanding multidrug resistance mechanisms, a major global health challenge, and seeks innovative solutions to combat bacterial infections. Additionally, he collaborates on projects involving diagnostic tools for detecting antimicrobial resistance, aiming to improve early detection and treatment strategies. Through his research, Dr. Bolla strives to bridge the gap between basic microbiology and clinical applications, working towards the development of effective antimicrobial strategies to tackle the increasing threat of drug-resistant bacteria worldwide.

Research Skills

Dr. Jean Michel Bolla possesses a diverse range of research skills, with expertise in molecular microbiology, biochemistry, and antimicrobial resistance. He has extensive experience in protein purification, bacterial physiology studies, and genetic manipulation of bacterial pathogens. His work in high-throughput screening techniques has been pivotal in identifying new inhibitors for efflux pumps in Gram-negative bacteria. He is proficient in drug discovery methodologies, including antibiotic susceptibility testing, mode-of-action studies, and bacterial membrane permeability analysis. Additionally, he has expertise in structural and functional analysis of bacterial outer membrane proteins, which play a crucial role in drug resistance. Dr. Bolla is also skilled in cell culture techniques, bioinformatics, and statistical analysis for interpreting large-scale screening data. His ability to secure major research funding highlights his competence in grant writing and project management. Furthermore, his teaching and mentorship experience demonstrate his ability to train and guide students in advanced microbiology research techniques. His research skills make him a valuable asset in the fight against antimicrobial resistance, as he continues to develop innovative solutions to combat bacterial infections.

Awards and Honors

Dr. Jean Michel Bolla has been recognized for his outstanding contributions to microbiology and antibiotic resistance research. In 2007, he was awarded the Inserm-Université Interface Contract, acknowledging his excellence in research and academic collaboration. His work in antimicrobial resistance has also been recognized through significant research grants from CNRS, ANR, and FEAMPA, underscoring the impact of his studies in drug discovery and bacterial resistance mechanisms. In 2019, his Bac-Screen platform was designated an Aix-Marseille University Technological Platform, a prestigious recognition that was renewed in 2023 for its critical role in antibiotic resistance research. His contributions to the field have also led to an international patent (WO 2023/139263 A1) for a diagnostic tool to detect drug resistance. Additionally, he has been an invited speaker at leading scientific conferences, including GRS-GRC Multidrug Efflux Systems and The 3rd International Electronic Conference on Antibiotics. His expertise and dedication to advancing microbial research have positioned him as a leading scientist in his field, earning him widespread recognition and respect.

Conclusion

Dr. Jean Michel Bolla is a highly accomplished microbiologist with a strong research background in antibiotic resistance and bacterial physiology. His contributions to understanding efflux-mediated resistance in Gram-negative bacteria have had a profound impact on the field. As Director of Research at Inserm U-1261, he has demonstrated exceptional leadership, securing major research funding and spearheading innovative screening platforms for antimicrobial resistance studies. His dedication to mentoring PhD students and postdoctoral researchers underscores his commitment to advancing scientific knowledge. Through his numerous research projects, international collaborations, and conference presentations, he continues to make significant strides in addressing the global challenge of antibiotic resistance. His patent for a diagnostic tool in antimicrobial resistance showcases his ability to translate research into real-world applications. Recognized through awards and honors, Dr. Bolla is a leading expert in microbiology and antimicrobial resistance. His work has positioned him as a key figure in drug discovery and bacterial resistance research, making him a strong contender for the Best Researcher Award. His career is a testament to scientific excellence, innovation, and dedication to global health challenges.

Publications Top Notes

  1. Title: RND Efflux Pump Induction: A Crucial Network Unveiling Adaptive Antibiotic Resistance Mechanisms of Gram-Negative Bacteria
    Authors: M. Novelli, Marine; J.M. Bolla, Jean Michel
    Year: 2024
    Citations: 5

  2. Title: Design and Synthesis of Novel Amino and Acetamidoaurones with Antimicrobial Activities
    Authors: A. Di Maio, Attilio; H. Olleik, Hamza; É. Courvoisier-Dezord, Élise; M. Maresca, Marc; M. Robin, Maxime
    Year: 2024
    Citations: 1

  3. Title: Antitubercular potential and pH-driven mode of action of salicylic acid derivatives
    Authors: J. Laudouze, Janïs; T. Francis, Thomas; E. Forest, Emma; P. Santucci, Pierre; J.F. Cavalier, Jean-François
    Year: 2024

  4. Title: Synthesis and antimicrobial testing of 5-fluorouracil derivatives
    Authors: M.U. Patil, Mrunal Unmesh; S. Krykun, Serhii; F. Garzino, Frédéric; J.M. Bolla, Jean Michel; M. Camplo, Michel
    Year: 2023
    Citations: 5

  5. Title: The membrane-active polyaminoisoprenyl compound NV716 re-sensitizes Pseudomonas aeruginosa to antibiotics and reduces bacterial virulence
    Authors: G. Wang, Gang; J.M. Brunel, Jean Michel; M. Preusse, Matthias; J.M. Bolla, Jean Michel; F. van Bambeke, Francoise
    Year: 2022
    Citations: 11

  6. Title: An Original and Efficient Antibiotic Adjuvant Strategy to Enhance the Activity of Macrolide Antibiotics against Gram-Negative Resistant Strains
    Authors: A. Troudi, Azza; J.M. Bolla, Jean Michel; N. Klibi, Naouel; J.M. Brunel, Jean Michel
    Year: 2022
    Citations: 4

  7. Title: The polyamino-isoprenyl potentiator NV716 revives disused antibiotics against Gram-negative bacteria in broth, infected monocytes, or biofilms, by disturbing the barrier effect of their outer membrane
    Authors: G. Wang, Gang; J.M. Brunel, Jean Michel; H. Rodríguez-Villalobos, Héctor; J.M. Bolla, Jean Michel; F. van Bambeke, Francoise
    Year: 2022
    Citations: 6

  8. Title: Nanoarchitectonics of Electrically Activable Phosphonium Self-Assembled Monolayers to Efficiently Kill and Tackle Bacterial Infections on Demand
    Authors: S. Carrara, Serena; F. Rouvier, Florent; S. Auditto, Sanjana; J.M. Bolla, Jean Michel; J.M. Raimundo, Jean Manuel
    Year: 2022
    Citations: 6

 

Nafiseh Esmaeil | Immunoltherapy | Best Researcher Award

Assoc Prof Dr. Nafiseh Esmaeil | Immunoltherapy | Best Researcher Award

Associate Professor and Isfahan University of medical sciences, Iran

Dr. Nafiseh Esmaeil is a dedicated immunologist and Associate Professor at Isfahan University of Medical Sciences. Her research, spanning from immunology to environmental medicine, is marked by significant contributions in understanding diseases like COVID-19 and Multiple Sclerosis. With a robust publication record and academic accolades, Dr. Esmaeil exemplifies excellence in research and is a deserving candidate for the Best Researcher Award.

Profile
Education

Dr. Esmaeil’s educational background is both extensive and impressive. She earned her Ph.D. in Immunology from Isfahan University of Medical Sciences between 2010 and 2014, where she developed a deep expertise in the immune system and its complexities. During her Ph.D., she also served as an Assistant Researcher at the Environmental Medicine Department of New York Medical School in 2013, which provided her with valuable international research experience. Prior to her doctoral studies, Dr. Esmaeil obtained her M.Sc. in Immunology from Mashhad University of Medical Sciences, further solidifying her foundation in this field. Her academic journey began with a B.Sc. in Laboratory Science from Shahid Beheshti University in Tehran, Iran, where she gained a solid understanding of the scientific principles that would later inform her research.

Professional Experience

Dr. Nafiseh Esmaeil has held several notable academic positions throughout her career. She began her academic journey as a research assistant from 2007 to 2010, where she honed her research skills and contributed to various projects in the field of immunology. Following this, she advanced to the position of Associate Professor in the Department of Immunology at the School of Medicine, Isfahan University of Medical Sciences, in Isfahan, Iran. In this role, Dr. Esmaeil has been instrumental in teaching, mentoring students, and leading research initiatives that contribute to the understanding of immune responses and related diseases.

Awards and Recognition

Dr. Esmaeil’s dedication to her research has been recognized through several honors and awards. In December 2012, she was named an Honored PhD Student at the Shahid Motahari Festival by Isfahan University of Medical Sciences, a testament to her outstanding academic performance and contributions to the field of immunology. The same year, she was also honored as a PhD student researcher in the medical school at Isfahan University of Medical Sciences, highlighting her significant research achievements during her doctoral studies.

Conclusion

Dr. Nafiseh Esmaeil is a highly accomplished immunologist whose career is marked by academic excellence, influential research, and a commitment to advancing the field of immunology. Her work has not only contributed to scientific understanding but has also had a tangible impact on public health through her research on diseases such as COVID-19 and Multiple Sclerosis. Dr. Esmaeil’s dedication, expertise, and significant contributions make her a strong candidate for the Best Researcher Award, reflecting her status as a leading figure in her field.

Publications Top Notes

Investigating the effect of Fusobacterium nucleatum on the aggressive behavior of cancer-associated fibroblasts in colorectal cancer

Authors: Eskandari-Malayeri, F., Rezeai, M., Narimani, T., Esmaeil, N., Azizi, M.

Journal: Discover Oncology

Year: 2024

Citations: 0

Decrease of Tregs cells and increase of exhausted Treg cells as the predictors of COVID-19 severity

Authors: Mirniam, S.M., Andalib, A., Radandish, M., Sami, R., Esmaeil, N.

Journal: Journal of Clinical Virology Plus

Year: 2024

Citations: 0

Pathway-Based Mendelian Randomization for Pre-Infection IL-6 Levels Highlights Its Role in Coronavirus Disease

Authors: Kamali, Z., Esmaeil, N., Thio, C.H.L., Vaez, A., Snieder, H.

Journal: Genes

Year: 2024

Citations: 0

Harnessing IL-10 induced anti-inflammatory response in maturing macrophages in presence of electrospun dexamethasone-loaded PLLA scaffold

Authors: Iraji Asiabadi, A., Esmaeil, N., Zargar Kharazi, A., Dabiri, A., Varshosaz, J.

Journal: Journal of Biomedical Materials Research – Part B Applied Biomaterials

Year: 2024

Citations: 0

Contradictory Effect of Lymphocyte Therapy and Prednisolone Therapy on CD3+CD8+CD56+ Natural Killer T Population in Women with Recurrent Spontaneous Abortion

Authors: Rezayat, F., Esmaeil, N., Rezaei, A., Sherkat, R.

Journal: Journal of Human Reproductive Sciences

Year: 2023

Citations: 0

Sodium-borohydride exfoliated bismuthene loaded with Mitomycin C for chemo-photo-radiotherapy of triple negative breast cancer

Authors: Varzandeh, M., Varshosaz, J., Labbaf, S., Esmaeil, N.

Journal: International Journal of Pharmaceutics

Year: 2023

Citations: 3

A 2-week combined high-intensity interval training regulates inflammatory status in young females with obesity

Authors: Soltani, N., Esmaeil, N., Marandi, S.M., Momen, T., Shahsanai, A.

Journal: Science and Sports

Year: 2023

Citations: 1

Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors

Authors: Ghaedrahmati, F., Esmaeil, N., Abbaspour, M.

Journal: Cancer Communications

Year: 2023

Citations: 10

Potential Therapeutic Effects of Human Amniotic Epithelial Cells on Gynecological Disorders Leading to Infertility or Abortion

Authors: Rezayat, F., Esmaeil, N., Rezaei, A.

Journal: Stem Cell Reviews and Reports

Year: 2023

Citations: 0

Resistance exercise training augments the immunomodulatory adaptations to aerobic high-intensity interval training

Authors: Soltani, N., Marandi, S.M., Hovsepian, V., Kazemi, M., Esmaeil, N.

Journal: European Journal of Sport Science

Year: 2023

Citations: 2

 

Hamza Hashmi | Immunotherapy | Best Researcher Award

Dr. Hamza Hashmi | Immunotherapy | Best Researcher Award

Assistant Professor at Memorial Sloan Kettering Cancer Center, United States.

Dr. Hamza Hashmi is a highly skilled oncologist with expertise in medical oncology, hematology, and cellular immunotherapy. He has a robust academic background, including a medical degree from King Edward Medical University in Lahore, Pakistan, followed by extensive postdoctoral training in internal medicine, hematology/oncology, and blood and marrow transplantation. Dr. Hashmi’s professional experience spans prestigious institutions such as Memorial Sloan Kettering Cancer Center and the University of Louisville. He is board-certified in internal medicine, medical oncology, and hematology, with active involvement in various professional organizations like the American Society of Hematology and the American Society of Clinical Oncology. Dr. Hashmi has received numerous honors and awards for his contributions to clinical trial enrollment and research. His research interests focus on advancing treatment modalities for hematologic malignancies, particularly through cellular immunotherapy and bone marrow transplantation. With a passion for education, Dr. Hashmi actively engages in teaching and mentoring activities, further enriching his contributions to the field of oncology.

Professional Profiles:

Education

Dr. Hamza Hashmi completed his medical education at King Edward Medical University in Pakistan, earning his M.B.B.S degree in 2011. He then underwent postdoctoral training, including roles as a Medical Officer in Internal Medicine and Hematology/Oncology in Lahore, Pakistan, followed by residencies and fellowships in Internal Medicine and Hematology Oncology in the United States. He specialized further in Blood and Marrow Transplantation and Cellular Immunotherapy at the H. Lee Moffitt Cancer and Research Center in Florida. Currently, he serves as an Assistant Professor at Memorial Sloan Kettering Cancer Center in New York, NY, demonstrating his commitment to advancing cancer care and research.

Professional Experience

Dr. Hamza Hashmi’s professional journey encompasses various roles in healthcare and academia. He began as a Medical Officer in Internal Medicine and Hematology/Oncology at Jamila Fareedy Hospital in Lahore, Pakistan. Later, he pursued residencies in Internal Medicine at Michigan State University and Hematology Oncology at the University of Louisville. Additionally, he underwent specialized training in Blood and Marrow Transplantation and Cellular Immunotherapy at the H. Lee Moffitt Cancer and Research Center in Florida. Currently, he holds an Assistant Professor position at Memorial Sloan Kettering Cancer Center in New York, NY, where he contributes to advancing cancer treatment and research. Throughout his career, Dr. Hashmi has demonstrated a commitment to providing high-quality patient care and contributing to the academic community through teaching and research.

Research Interest

Dr. Hamza Hashmi’s research interests primarily focus on hematologic malignancies, particularly multiple myeloma and lymphoma. He is particularly interested in exploring novel treatment modalities, including cellular immunotherapy and bone marrow transplantation, to improve outcomes for patients with these conditions. Additionally, Dr. Hashmi is interested in studying the molecular mechanisms underlying disease progression and treatment resistance in hematologic cancers. He is actively involved in clinical research aimed at identifying predictive biomarkers and developing targeted therapies tailored to individual patients. Overall, his research aims to advance our understanding of hematologic malignancies and develop innovative treatment strategies to improve patient outcomes.

Award and Honors

Dr. Hamza Hashmi has been recognized with prestigious awards for his outstanding contributions to oncology. Among these accolades is the Top Ten Publishers Club Award bestowed upon him by the Medical University of South Carolina in 2023. This award underscores Dr. Hashmi’s exceptional research output and academic contributions, positioning him as one of the top scholars in his field. Additionally, he has been honored with the Excellence in Clinical Trial Enrollment Award from the same institution in the same year. This recognition highlights Dr. Hashmi’s commitment to advancing cancer treatment through clinical research and his significant impact on patient care. These awards serve as testament to Dr. Hashmi’s dedication, expertise, and leadership in the field of oncology.

Research Skills

Dr. Hamza Hashmi possesses a diverse set of research skills honed throughout his academic and professional journey. With a strong foundation in medical oncology and hematology, he demonstrates proficiency in conducting clinical trials, analyzing data, and interpreting results. His expertise extends to cellular immunotherapy and bone marrow transplantation, areas where he has contributed significantly to the advancement of treatment modalities for hematologic malignancies. Dr. Hashmi is adept at literature review and synthesis, enabling him to stay abreast of the latest developments in oncology research. Furthermore, he excels in study design, protocol development, and patient recruitment, ensuring the successful implementation of research projects. His collaborative spirit and effective communication skills facilitate interdisciplinary collaboration and knowledge sharing, fostering innovation in cancer care. Overall, Dr. Hashmi’s research skills position him as a valuable asset in the pursuit of novel therapies and improved outcomes for cancer patients.

Publications

  1. Efficacy and safety of idecabtagene vicleucel in patients with relapsed–refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre study
    • Authors: Dima, D.; Rashid, A.; Davis, J.A.; Anwer, F.; Ahmed, N.
    • Journal: British Journal of Haematology
    • Year: 2024
  2. Safety and efficacy of eltrombopag in patients with post-CAR T cytopenias
    • Authors: Wesson, W.; Ahmed, N.; Rashid, A.; Abdallah, A.-O.; Hashmi, H.
    • Journal: European Journal of Haematology
    • Year: 2024
  3. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience
    • Authors: Dima, D.; Davis, J.A.; Ahmed, N.; Abdallah, A.-O.; Hashmi, H.
    • Journal: Transplantation and Cellular Therapy
    • Year: 2024
  4. Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma
    • Authors: Davis, J.A.; Dima, D.; Ahmed, N.; Abdallah, A.-O.; Hashmi, H.
    • Journal: Transplantation and Cellular Therapy
    • Year: 2024
  5. Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment
    • Authors: Sidana, S.; Peres, L.C.; Hashmi, H.; Patel, K.K.; Hansen, D.K.
    • Journal: Haematologica
    • Year: 2024
  6. Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy
    • Authors: Oluwole, O.O.; Dholaria, B.; Knight, T.E.; Anderson, L.D.; Hamadani, M.
    • Journal: Transplantation and Cellular Therapy
    • Year: 2024
  7. Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy
    • Authors: Peres, L.C.; Oswald, L.B.; Dillard, C.M.; Hansen, D.K.; Patel, K.
    • Journal: Blood Advances
    • Year: 2024
  8. Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab-naïve relapsed multiple myeloma
    • Authors: Dima, D.; Mansour, R.; Davis, J.A.; Abdallah, A.-O.; Hashmi, H.
    • Journal: European Journal of Haematology
    • Year: 2024
  9. Impact of age, obesity, and renal impairment on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma
    • Authors: Gaffney, K.J.; Bakos, J.K.; Velayati, A.; Hess, B.T.; Hashmi, H.
    • Journal: Journal of Oncology Pharmacy Practice
    • Year: 2024
  10. Impact of race and ethnicity on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma
    • Authors: Davis, J.A.; Thurlapati, A.; Weeda, E.; Green, K.; Hashmi, H.
    • Journal: Annals of Hematology
    • Year: 2024